GENOMIC-PERSONALIZED MEDICINE CONFERENCE AGENDA

Coordinated by PHARMEXCIL

GENOMIC-PERSONALIZED MEDICINE CONFERENCE Hyderabad International Convention Center, Hyderabad February 19, 2014 Chairman: Prof. Donald W. Weaver, Surgeon-in-Chief, Detroit Medical Center (DMC), Chief of Surgery at Harper University Hospital, Chairman of Department of Surgery, Wayne State University School of Medicine, USA Convener: Dr. Ramesh B. Batchu, Associate Professor, Dept Surgery, School of Medicine Director, Division of Surgical Oncology & Developmental Therapeutics, Dept Immunology and Microbiology, John D Dingell VAMC, Wayne State University

Draft Program Agenda 09:30-10:00 Hrs

“Personalized Medicine: Tailor-made for individual patient” Personalized medicine is the ability to determine an individual’s unique molecular characteristics to propose customization of medical care more finely suited to an individual’s disease. The availability of genetic information due to successful human genome project has played a major role in the ability to predict an individual’s susceptibility to diseases. This will allow treatment protocols that may help reduce the extent to disease that is specific to individual.

Prof. Donald W. Weaver MD, FACS, Surgeon-in-Chief, Detroit Medical Center (DMC), Chief of Surgery at Harper University Hospital, Chairman of Department of Surgery, Wayne State University School of Medicine, USA

10:00-10:20 Hrs

Genomic Medicine in Perinatal Diagnosis and Therapy Identification of conditions that can be treated before or immediately after birth using genome analysis will allow diagnosis of unborn baby. Recent discoveries showing circulating cells of fetus in pregnant women allowed sequencing of the fetal genome.

This will allow perinatal diagnosis with treatable disorders before symptoms become noticeable. Initially, missing or extra chromosomes, such as in the Down syndrome, can be easily identified. This is just tip of the iceberg, and that diagnosing individual gene defects will be the future.

Valarie Parisi, MD, PhD, MBA, Dean School of Medicine, Wayne State University, USA

10:20-10:40 Hrs

Personalized Therapeutic Vaccines Therapeutic vaccinology will allow the development of personalized vaccines based on our increasing understanding of immune response phenotype: genotype information.

Rapid advances in developing such data are already occurring for numerous diseases and newly available data suggest that some vaccine-related adverse events may also be preventable based on genetic prediction.

For registrations Contact – info@bioasia.in | Telephone: +91-40-6644-6477/6577

Coordinated by PHARMEXCIL

Dr. Bala Krishna Kolli, Rosalinda Franklin University of Medicine and Science, North Chicago, IL, USA 10:40-11:00 Hrs

Tea / Coffee Break

11:00-11:20 Hrs

Urological cancers, biomarkers and cancer pathway inhibitors Immune status every tumor and the way its cells respond to the local environment is different, based on the genetic profile of patients. The tumor grade may be the same from patient to patient, but the pathways for escape and resistance may be different.

Genomics and proteomics guided treatment of individual patients is the direction we should be going to manage malignancies. This holds true not only when it comes to predicting progression and aggression of tumors where we need to be pairing therapeutics based on the genetic/protein marker. Each patient with urological cancer has a distinct histology, a different clinical course and responds differently to therapy.

For example genomic studies identifying the genes for kidney cancer, such asfumarate hydratase, and succinate dehydrogenase have significantly altered the ways in which patients with kidney cancer are managed.

Prof. Jose Edson Silva MD, Department of Urology, Wayne State University School of Medicine, University Health Center, USA

11:20-11:40 Hrs

Gene-based treatment for Head and Neck Cancers Although some head and neck cancers are diagnosed early in the disease progression, unfortunately silent lesions are not diagnosed until regional spread has already occurred. The stage at time of diagnosis for a cancer of the larynx with early symptoms of hoarseness is much lower than that of a base of tongue cancer which often lacks symptoms till latter in the disease course. . Infection with the human papilloma virus (HPV) increases one’s odds of developing squamous cell carcinoma of the oral pharynx. As smoking has decreased, the incidence of HPV associated cancers has increased. Understanding the genetic basis of this specific subtype of cancer could allow therapeutic targeting of affected pathways for a stratified medicine approach.

Gene profile analysis of various head and neck cancers revealed altered pathways in p53 and RB mutation and copy number alteration of PI3 kinase pathway. Additional observations of alternative pathways have been made in cancers of the thyroid. Whole genome sequencing and identification gene expression patterns will be required to gain a complete understanding of the genetic basis of head and neck cancers to provide the foundation for the development of effective forms of therapy.

Prof. John R Jacobs MD FACS, Departments Otolaryngology Head and Neck Surgery, Wayne State University, Karmanos Cancer Center, USA

For registrations Contact – info@bioasia.in | Telephone: +91-40-6644-6477/6577

Coordinated by PHARMEXCIL 11:40-12:00 Hrs

Genetic Immunotherapy with Dendritic Cells for Individualized Cancer Vaccine Dendritic cells (DC) are highly specialized antigen-presenting immune cells and key regulators of the immune responses and orchestrate innate and adoptive immunities throughout the body. They are responsible for identifying tumor markers to activate cytotoxic T lymphocytes, which then multiply and attack only the diseased cells, not normal healthy cells. This is a potent form of immunotherapy to harness the body’s own immune system to fight cancer. Use of non-pathogenic recombinant adenoassociated viral (rAAV) vectors can achieve high levels of intracellular tumor specific gene expression in DCs with much lower doses of vector and generation of robust cellular anti-tumor immune responses. Gene-vector based immunotherapy with DCs would pave the way for development of a therapeutic vaccine strategy to achieve durable tumor regression specific to individual patients.

Prof. Selvarangan Ponnazhagan, Endowed Professor in Experimental Cancer Therapeutics, The University of Alabama at Birmingham, USA

12:00-12:20 Hrs

Adeno-associated Viral vectors in Genomic Medicine and cell based treatment Gene therapy with traditional viral vectors is limited by a variety of practical and theoretical concerns, such as the immunogenicity of viral capsid proteins and insertional mutagenesis. Adeno-associated virus (AAV) is small, 4.7kb, non-enveloped DNA virus initially identified as a contaminant in adenoviral preparations.

Bioengineered recombinant AAV (rAAV) vectors are preferred for gene therapy due their lack of pathogenicity, wide range of infectivity, and ability to establish long-term transgene expression in non-dividing cells. Further, with only a modest frequency of integration into the host genome, they avoid insertional mutagenesis. Finally, rAAV only weakly induce innate immune responses when compared with other viral-based vector systems. rAAV have yielded promising results in an increasing number of somatic gene therapy clinical trials without any significant adverse events. However, despite the well-established safety of rAAV vectors for in vivo gene transfer, several challenges remain, such as achieving only low levels of transduction in targeted organs and cytoplasmic degradation of a high percentage of virion during intracellular trafficking to the nucleus. Indeed, rAAV capsids are tyrosine phosphorylated, marking them for ubiquitin-proteasome mediated degradation in the cytosol. This produces the need to use higher doses of vector in order to obtain therapeutically-relevant concentrations in patients. Novel hybrid vectors which combines properties of a DNA family shuffled rAAV-DJ vector with tyrosine capsid mutations in order to achieve high levels of both transduction efficiency and trans-gene expression and their utility in genomic medicine will be discussed.

Dr. Ravindra B Potti, Associate Professor, Department of Biotechnology, Sreenidhi Institute of Science and Technology, Hyderabad

12:20-13:00 Hrs

Interaction and Close

For registrations Contact – info@bioasia.in | Telephone: +91-40-6644-6477/6577